Absci recently detailed two of its drug discovery machine learning (ML) breakthroughs, and presented validation of its in-silico lead optimization models. Absci’s first breakthrough is an ML model for quantitative prediction of antibody target affinity, enabling computational predictions of binding strength. The second is an ML model designed to score the ‘naturalness’ of antibody variants . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Learning Curve: Absci, NVIDIA Partner on Antibody Design appeared first on GEN – Genetic Engineering and Biotechnology News.
